Eli Lilly マネジメント

マネジメント基準チェック /24

Eli Lillyの CEO はDave Ricksで、 Jan2017年に任命され、の在任期間は 9.17年です。の年間総報酬は$ 36.70Mで、 4.6%給与と95.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.091%を直接所有しており、その価値は€ 641.98M 。経営陣と取締役会の平均在任期間はそれぞれ6.5年と9.8年です。

主要情報

Dave Ricks

最高経営責任者

US$36.7m

報酬総額

CEO給与比率	4.63%
CEO在任期間	9.2yrs
CEOの所有権	0.09%
経営陣の平均在職期間	6.5yrs
取締役会の平均在任期間	9.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Eli Lilly の収益と比較して、Dave Ricks の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2025	US$37m	US$2m	US$21b
Sep 30 2025	n/a	n/a	US$18b
Jun 30 2025	n/a	n/a	US$14b
Mar 31 2025	n/a	n/a	US$11b
Dec 31 2024	US$29m	US$2m	US$11b
Sep 30 2024	n/a	n/a	US$8b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b

報酬と市場: Daveの総報酬 ($USD 36.70M ) は、 Italian市場 ($USD 4.20M ) の同規模の企業の平均を上回っています。

報酬と収益: Daveの報酬は過去 1 年間で 20% 以上増加しました。

CEO

Dave Ricks (57 yo)

9.2yrs

在職期間

US$36,698,337

報酬

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Ricks	Chairman & CEO	9.2yrs	US$36.70m	0.091% € 642.0m
Lucas Montarce	Executive VP & CFO	1.5yrs	US$8.48m	0.0018% € 12.8m
Daniel Skovronsky	Chief Scientific & Product Officer and President of Lilly Research Laboratories	7.8yrs	US$17.79m	0.026% € 185.5m
Anat Hakim	Executive VP	6.1yrs	US$9.85m	0.0062% € 43.7m
Jacob Van Naarden	Executive VP & President of Lilly Oncology	no data	US$7.59m	0.0041% € 28.6m
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	13.3yrs	データなし	0.00059% € 4.1m
Diogo Rau	Executive VP and Chief Information & Digital Officer	4.8yrs	US$5.10m	0.0029% € 20.7m
Michael Czapar	Director of Investor Relations	7.3yrs	データなし	データなし
Eric Dozier	Executive VP & Chief People Officer	3.3yrs	データなし	0.0017% € 11.7m
Ilya Yuffa	Executive VP and President of Lilly USA & Global Customer Capabilities	5.4yrs	データなし	0.0036% € 25.5m
Patrik Jonsson	Executive VP & President of Lilly International	6.5yrs	US$3.92m	0.0069% € 48.2m
Frank Cunningham	Senior Vice President of Global Value & Access	6.6yrs	データなし	データなし

6.5yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: 1LLYの経営陣は経験豊富で経験豊富です（平均在職期間は6.5年）。

取締役

名称	ポジション	在職期間	報酬	所有権
David Ricks	Chairman & CEO	9.2yrs	US$36.70m	0.091% € 642.0m
Gabrielle Sulzberger	Independent Director	5.2yrs	US$365.50k	0.000010% € 70.3k
Sidney Taurel	Chairman Emeritus	17.2yrs	US$13.06m	データなし
Jon Erik Fyrwald	Independent Director	20.3yrs	US$343.80k	0.00019% € 1.3m
Ralph Alvarez	Independent Director	16.9yrs	US$361.00k	0.000080% € 562.6k
Carolyn Bertozzi	Independent Director	less than a year	US$7.68k	0.00022% € 1.5m
William Kaelin	Independent Director	13.8yrs	US$392.00k	データなし
Mary Hedley	Independent Director	3.8yrs	US$339.00k	0.000040% € 281.3k
Juan Luciano	Lead Independent Director	10.1yrs	US$398.00k	データなし
Katherine Baicker	Independent Director	14.3yrs	US$361.00k	データなし
Jamere Jackson	Independent Director	9.4yrs	US$368.00k	0.000020% € 140.6k
Kimberly Johnson	Independent Director	5.1yrs	US$336.00k	データなし

9.8yrs

平均在職期間

63.5yo

平均年齢

経験豊富なボード: 1LLYの取締役会は経験豊富であると考えられます ( 9.8年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/03/24 13:03
終値	2026/03/24 00:00
収益	2025/12/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを作成するために使用した分析モデルの詳細は、当社のGithubページでご覧いただけます。また、レポートの使用方法を説明するガイドや、YouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Eli Lilly and Company 27 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。53

アナリスト	機関
David Toung	Argus Research Company
Emily Field	Barclays
Kerry Holford	Berenberg

Eli Lilly マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Eli Lilly and Company, Annual General Meeting, May 04, 2026

Insufficient new directors

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery

Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025

Recent updates

Eli Lilly And Company Demonstrates Significant Reductions In A1C And Weight With Retatrutide In First Phase 3 Trial For Treatment Of Type 2 Diabetes

Eli Lilly And Company Announces Positive Phase 3 Results For EBGLYSS In Pediatric Patients With Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Company, Annual General Meeting, May 04, 2026

Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding Actos

Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage Options

Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia Areata

Eli Lilly and Company Announces Detailed Results from ACHIEVE-3

Eli Lilly and Company Announces the U.S. Food and Drug Administration Approves a Label Expansion for Zepbound® (tirzepatide)

Eli Lilly and Company Presents New Long-Term Data from Eli Lilly and Company's Omvoh (mirikizumab-mrkz)

Eli Lilly and Company Announces Positive Topline Results from Taltz (Ixekizumab) and Zepbound (Tirzepatide)

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of Retevmo

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Orna Therapeutics, Inc. in a transaction valued at $2.4 billion.

Full year 2025 earnings released: EPS: US$22.95 (vs US$11.76 in FY 2024)

Eli Lilly and Company Provides Earnings Guidance for the Full Year 2026

Now 21% undervalued

Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026

Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian Cancer

Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk

Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.

Ventyx Biosciences Reportedly in $1 Billion Acquisition Talks with Eli Lilly

Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).

Eli Lilly and Company Announces Oral GLP-1 Orforglipron

Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trial

Now 20% undervalued

Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical Trial

Insufficient new directors

Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual Meeting

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of Eloralintide

Third quarter 2025 earnings released: EPS: US$6.21 (vs US$1.08 in 3Q 2024)

Eli Lilly and Company Raises Earnings Guidance for the Year 2025

Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative Colitis

Eli Lilly and Company's Omvoh Demonstrates Early and Sustainable Improvement in Bowel Intention Outcomes for Patients with Ulcerative Colitis

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.

Eli Lilly and Company Announces Results from the Primary Overall Survival Analysis of the Phase 3 Monarche Trial

Eli Lilly and Company to Report Q3, 2025 Results on Oct 30, 2025

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 Trials

Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery

Eli Lilly and Company's Omvoh (mirikizumab-mrkz) Is the First and Only Interleukin-23p19 (IL-23p19) to Help Patients with Moderately Active Ulcerative Colitis Achieve Sured, Long-Term Outcomes Through Four Years

Investor sentiment improves as stock rises 16%

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Inluriyo (imlunestrant) for Adults with ER+, HER2, ESR1-Mutated Advanced or Metastatic Breast Cancer

Eli Lilly and Company Announces Detailed Results from Surpass-PEDS, the First Phase 3 Trial to Evaluate the Safety and Efficacy of Mounjaro

Eli Lilly and Company Announces Positive Topline Results from ACHIEVE-3

Eli Lilly and Company Launches TuneLab Platform to Give Biotechnology Companies Access to AI-Enabled Drug Discovery Models Built Through over $1 Billion in Research Investment

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-313 Clinical Trial of Jaypirca

Eli Lilly and Company Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed KRAS G12C-Mutant Lung Cancer

Eli Lilly and Company Announces Positive Topline Results from the Primary Overall Survival (OS) Analysis of the Phase 3 MonarchE Trial

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 Attain-2 Trial

Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025

Ken Paxton Files Lawsuit in State Court Against Eli Lilly and Co

New major risk - Earnings quality

Second quarter 2025 earnings released: EPS: US$6.29 (vs US$3.29 in 2Q 2024)

Eli Lilly and Company Raises Earning Guidance for the Year 2025

Investor sentiment deteriorates as stock falls 17%

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 Attain-1 Trial

Eli Lilly and Company Announces Topline Results from SURPASS-CVOT

Eli Lilly and Company Announces Results from the Long-Term Extension (LTE) of the Phase 3 Trailblazer-Alz 2 Study

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 BRUIN CLL-314 Clinical Trial of Jaypirca

Eli Lilly and Company Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) in Early Symptomatic Alzheimer's Disease

Eli Lilly and Company to Report Q2, 2025 Results on Aug 07, 2025

Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease

First quarter dividend of US$1.50 announced

Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025

マネジメント基準チェック /24